Oncology Institute, INC

The Oncology Institute, Inc. has officially rebranded to Starling Oncology, Inc., with its stock set to trade under the new ticker symbol STLN on Nasdaq.

The Oncology Institute, Inc. has successfully refinanced its existing debt with a new $75 million term loan facility from OrbiMed Opportunities (CA) V LLC, repaying its prior convertible notes.

The Oncology Institute disclosed that a third-party vendor cybersecurity incident resulted in unauthorized access to patient data.

The Oncology Institute, Inc. has prepared and furnished an investor presentation for upcoming meetings with investors.

The Oncology Institute, Inc. announced improved Q4 and full-year 2025 financial results, driven by capitated care expansion, and projects positive Adjusted EBITDA for 2026.

The Oncology Institute announced the appointment of Kim Tzoumakas, a seasoned healthcare executive, to its Board of Directors, effective February 23, 2026.

The Oncology Institute reports significant revenue growth in Q3 2025, driven by dispensary and patient services, but faces continued net losses and a negative stockholders' equity, while taking steps to improve liquidity.

The Oncology Institute, Inc. reported increased revenue and improved operational efficiency in Q2 2025, alongside continued net losses and strategic capital raises.

The Oncology Institute's Q1 2025 results show a revenue increase driven by dispensary growth, alongside strategic debt management and a private placement to bolster liquidity.

The Oncology Institute's Q3 2024 results show a significant increase in dispensary revenue, offsetting a slight decrease in patient services revenue, while the company continues to expand its value-based oncology services.

The Oncology Institute's Q2 2024 results show a revenue increase driven by dispensary growth, offset by a decrease in patient services revenue, and a net loss of $15.5 million.

The Oncology Institute has filed an amendment to its Q1 2024 10-Q report to correct inadvertently omitted language in the certifications related to internal control over financial reporting.

The Oncology Institute, Inc. reported a 27.8% increase in total operating revenue for 2025, alongside a significant reduction in net loss and improved Adjusted EBITDA.

The Oncology Institute's 10-K filing reveals a year of revenue growth tempered by net losses and strategic shifts in a dynamic healthcare landscape.

The Oncology Institute has filed an amendment to its 2023 annual report to correct omissions in the certifications of its CEO and CFO regarding internal controls over financial reporting.

The Oncology Institute, Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

The Oncology Institute's 10-K filing provides a detailed description of its capital stock, including common stock and redeemable warrants, outlining shareholder rights and warrant terms.

Mohit Kaushal, a Director of Oncology Institute, Inc., received 33,133 shares of common stock on July 27, 2026.

Anne Mcgeorge, a Director of Oncology Institute, Inc., received 41,165 shares of common stock on July 27, 2026.

Mark L Pacala, a Director of Oncology Institute, Inc., received 30,120 shares of common stock on July 27, 2026.

Mark Stolper, a Director of Oncology Institute, Inc., received 31,124 shares of common stock on July 27, 2026.

Kimberly Jo Tzoumakas, a Director of Oncology Institute, Inc., received 29,116 shares of common stock on July 27, 2026.

Brad Hively, a Director of Oncology Institute, Inc., received 27,108 shares of common stock on July 27, 2026.

The Oncology Institute will hold its annual stockholders meeting on May 7, 2025, and is seeking approval for a reverse stock split.

The Oncology Institute announces its annual stockholders meeting on May 7, 2025, featuring proposals including the election of directors, ratification of the accounting firm, and a potential reverse stock split.

The Oncology Institute will hold its annual stockholders meeting on June 13, 2024, to elect directors, ratify the appointment of BDO USA, P.C., and approve the issuance of shares related to convertible notes and warrants.

The Oncology Institute will hold its annual stockholders meeting virtually on June 13, 2024, to vote on the election of directors, ratification of the independent accounting firm, and approval of potential share issuances related to convertible notes and warrants.

M33 Growth I LP and TOI M, LLC have reduced their beneficial ownership in The Oncology Institute, Inc. through an in-kind distribution of shares to their respective partners.

M33 Growth I LP and TOI M, LLC sold a combined 6.7 million shares of The Oncology Institute, Inc. common stock for $3.09 per share, with M33 LP entering a 180-day lock-up agreement.

Ravi Sarin and OncologyCare Partners, LLC have ceased to be beneficial owners of more than 5% of The Oncology Institute, Inc.'s common stock due to dilution from a recent private placement.

M33 Growth I LP, M33 Growth I GP LLC, and TOI M, LLC have increased their beneficial ownership in The Oncology Institute, Inc. to 19.99% through a recent private placement of common stock and warrants.

Jorey Chernett has reported beneficial ownership of 10.2% of Oncology Institute, Inc.'s common stock as of March 13, 2026.

Jorey Chernett has reported beneficial ownership of 5.2% of the common stock of Oncology Institute, Inc. in a Schedule 13G filing.

FOG Ventures Investments, LLC and Daniel Murillo have filed an amended Schedule 13G, confirming their complete exit from beneficial ownership of Oncology Institute, Inc. common stock.